Serious Warning Signs Severe abdominal pain: Especially if sudden onset, radiating to back, or with vomiting (possible pancreatitis, occurred in 0.3% of patients) Severe vomiting: If unable to keep any fluids down for 24 hours (dehydration risk) Signs of dehydration: Dark urine, dizziness on standing, confusion, decreased urination (acute kidney injury risk) Vision changes: Blurred vision, eye pain (rare but requires evaluation) Rapid heart rate: Persistent heart rate over 100 at rest (some increase normal, average 2-4 bpm, but sustained tachycardia needs evaluation) Suicidal thoughts: Any thoughts of self-harm (under 1% occurrence but requires immediate support) Severe allergic reaction: Difficulty breathing, throat swelling, severe rash (anaphylaxis requires emergency care) Lump in neck: Especially with difficulty swallowing (thyroid concern, rare but part of class warning) Trust your instincts
Proteomic signature of semaglutide treatment In STEP 1, statistical learning and feature selection were applied to derive a protein signature that distinguished participants receiving semaglutide from participants receiving placebo based on proteomic changes at end of treatment
Headaches, fatigue, and mood changes can occur during the first one to two weeks after discontinuation in some patients
This emphasizes the importance of individualized care plans for elderly diabetes patients, balancing glycemic targets with the risk of hypoglycemia and other adverse effects
The locally available method (LightPower assay) failed to identify genotype 6 non-a/non-b, which highlights that methods using 5UTR information only should not be used in Cambodia
Analysis of blood parameters confirmed improvements in key markers of glucose and lipid metabolism, such as blood lipid levels, cholesterol, liver damage markers, and HOMA-IR
